Wondering where the venture capital funding has gone in the healthcare industry? According to CB Insights, it’s the following 10 cities–for Q3 ’13 at least. (Listed in order of amounts of deals; note that though San Francisco saw more deals, San Diego saw more funding.) San Francisco, Calif.: 7 deals, $77 million San Diego, Calif.: […]
The experimental lupus treatment being developed by Argos Therapeutics is showing promise in early stage clinical trials, but the questions remain whether it’s enough progress to attract interest from a potential pharmaceutical partner. Argos released positive phase 1 clinical trial results for AGS-009 at the 2012 European League Against Rheumatism Congress (EULAR) in Berlin, […]
Immunotherapy company Argos Therapeutics, which last month withdrew plans for a $65 million initial public offering, has now secured a $25 million round of financing to start phase 3 clinical trials on its novel kidney cancer treatment. Forbion Capital led the series D round, joined by fellow existing investors TVM Capital, Lumira Capital, Intersouth Partners, […]
Immunotherapy company Argos Therapeutics has pulled back on its plans for an initial public offering and leaves it needing to find another way to finance phase 3 clinical trials for its novel kidney cancer treatment. In a letter filed with securities regulators, Argos simply said that it was withdrawing its registration statement “due to market […]
Immunotherapy company Argos Therapeutics has developed a new technology that could set it apart from other biotechnology cancer treatments — an approach that’s completely personalized to the patient and also costs less. But that’s just the beginning. This personalized medicine platform technology is also being developed to treat other diseases such as HIV. With positive […]
